Apimeds Pharmaceuticals Us, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
AMEX
Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have disclosed a 9.99% beneficial ownership stake in Apimeds Pharmaceuticals US, Inc. through convertible notes.